Faricimab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Faricimab and local guidelines before prescribing.
Anti-VEGF agent
Mechanism
Bispecific anti-VEGF and anti-angiopoietin-2 antibody.
Uses
Neovascular AMD, diabetic macular oedema.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Cataract, eye pain, conjunctival haemorrhage.
Interactions
None significant.
Contraindications and cautions
Ocular infection
Monitoring
Visual acuity
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Intravitreal; longer intervals possible.
More from the textbook: uses, cautions and other points
- Diabetic macular oedema - intravitreal anti-VEGF (aflibercept, ranibizumab, faricimab) first line; dexamethasone or fluocinolone implants; focal laser.
Ophthalmology: Retinal Visual Loss - Macular oedema: Intravitreal anti-VEGF (e.g. aflibercept, ranibizumab, faricimab), steroid implants or laser.
Endocrinology: Diabetes - Macular oedema - intravitreal anti-VEGF injections (ranibizumab, aflibercept, faricimab) or a dexamethasone implant .
Ophthalmology: Retinal Visual Loss - Aflibercept , ranibizumab (including biosimilars), faricimab (also blocks angiopoietin-2), and others.
Ophthalmology: Retinal Visual Loss - Aflibercept / ranibizumab / faricimab (intravitreal) | Anti-VEGF for wet AMD, diabetic macular oedema and vein occlusion oedema; repeated injections; endophthalmitis risk.
Ophthalmology: Retinal Visual Loss
Where it is discussed in the book
- Endocrinology: Diabetes (1 mention)
- Ophthalmology: Retinal Visual Loss (4 mentions)